WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods. The method was developed in collaboration with the laboratory of Bradley E. Bernstein, MD, PhD through grant R01-HG009269 from the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI).
- However, this platform provides multifaceted information in single cell resolution, which will be helpful for cancer diagnosis and assessing its causality.
- Using this epitranscriptomic method to profile single cells, researchers will have the power to reveal insights into complex biological pathways beyond those that current methods allow.
- SeqLLs exclusive True Single Molecule Sequencing (tSMS) technology enables direct sequencing of millions of individual molecules.
- The tSMS platform offers maximum flexibility and avoids many of the challenges common for standard sequencing approaches.